@nicogagelmann.bsky.social shares findings that longer telomeres in donors ≥35 are associated with reduced graft failure and lower non-relapse mortality following allogeneic HCT. #ASH25
Don't get left out at sea! Prepare now for ASH-a-Palooza at #ASH25🐬
◽Sign up early for Blood Buddy speed mentoring: https://ow.ly/Cafw50XA6Gt
◽Arrive by 11:45 a.m. for the Global Hematology Trainee Networking Lunch
◽Join the AAP treasure hunt ( in the #ASH25 app)
#ASHTrainee ASH Education
The #ASH25 virtual platform is now live! Log in now using the ASH username and password you used to register for the annual meeting: https://ow.ly/MmlR50XBiMT
🌟Your bonus and preview content await. Plus, explore networking, exhibits, and more on the virtual platform! #HemeSky #MedSky
Your go-to social media guide for #ASH25 is here. Find tips on following updates, taking part in conversations, using the official hashtags, and entering fun challenges with #ASHNewsDaily.
Read now: https://ow.ly/tEgJ50XxAP6
#HemeSky #ASHaiku #ASHKudos #ASHRunWalk #ASHScavengerHunt
The ASH annual meeting is the premier venue for #hematology collaborations across borders 🌏
#ASHThrowback to a meeting with ASH and the Mediterranean Partner Societies at #ASH24. Belinda Avalos, MD #ASH25
International community, share your throwbacks from past ASH meetings! #HemeSky
Finally in Boston!
Honored to join @danafarber.bsky.social, eager to learn and contribute in this terrific community @coleman-lindsley.bsky.social.
A place of science, purpose and hope.
Thank you all who made COSTEM 2025 THE event for transplant & cellular therapies❗️
Faculty who fight REAL debates
Audience that ask REAL questions
Unity amid controversy🙏
See you 1-3 October 2026 in Berlin again!
Last Call for Early Bird Registration
Join us at the 10th COSTEM Congress!
🗓️ September 25–28, 2025
📍 Berlin, Germany
Don't miss your chance to save – Early Bird registration closes July 31st!
costem.cme-congresses.com/registration/
🎥 Check out our recent interview from #CART25 with @nicogagelmann.bsky.social, in which he highlights the need to address inequality & inequity in access to #CARTCell therapy across Europe:
👉 buff.ly/4gBhWeD
#ImmunoOnc #HemOnc #Hematology #MedSky #BloodSky #HemeSky
Out now in Blood Advances 🙌🏽
Our work from Princess Margaret Cancer Centre evaluating the role of PTCy in matched sibling donor allogeneic transplantation!
Also read this excellent commentary by my good friend @nicogagelmann.bsky.social 👇🏽
ashpublications.org/bloodadvance...
MAKE CAR-T AFFORDABLE AGAIN
Terrific learning experience from cellular therapy programs in India, Slovenia, Brazil and Turkey
#CART25
Let's learn hematology in 2025🩸
Day 27: hemophilia characteristics
🎉Finally published🎉
Cilta-cel vs ide-cel for relapsed or refractory multiple myeloma
@hemasphere-journal.bsky.social
onlinelibrary.wiley.com/doi/full/10....
🎉Finally published🎉
Clearance of driver mutations after transplantation for myelofibrosis
@nejm.org
www.nejm.org/doi/full/10....
In a single-group, single-center study, clearance of driver mutations 30 days after bone marrow transplantation predicted long-term disease-free survival in patients with myelofibrosis. Read the full study results: nej.md/4fQNdKn
#MedSky
Talquetamab plus Teclistamab in Multiple Myeloma (RedirecTT-1 study) nej.md/4iZNYTY
Driver Mutations in Myelofibrosis (single-group, single-center study) nej.md/4fQNdKn
Thanks Anand!!
a blockbuster paper by @nicogagelmann.bsky.social et al in @nejm.org on the impact of driver mutation clearance in patients with MF that underwent allo-HCT!
www.nejm.org/doi/full/10....
🎉Finally published🎉
Clearance of driver mutations after transplantation for myelofibrosis
@nejm.org
www.nejm.org/doi/full/10....
@nicogagelmann.bsky.social
#ASHKudos for the award. Glad that you had fun at #ASH24!
What a wonderful #ASH24
Honored to receive @ash-hematology.bsky.social Abstract Achievement Award, meet friends, celebrate colleagues' achievements, enjoy terrific science and San Diego.
Until next year 🙏🩸❤️
Tomorrow @nicogagelmann.bsky.social will take over our Twitter account, bringing you live updates & expert takes straight from #ASH24 🗞️🩸📱
Give us a follow over there so you don't miss the action 👉 x.com/VJHemOnc 👀
Now @nicogagelmann.bsky.social on molecular genetics and JAKi impact on allo-HCT in MF
-1800 rux treated pts
-early allo in high-risk PMF and SMF seems to be best timing
-early allo in TP53 may offer survival benefit
🎉Finally out and timely for #ASH24 @ash-hematology.bsky.social 🎉
Happy to share our international work suggesting bispecific antibodies as standard of care for relapse after CAR-T in multiple #myeloma #mmsm
t.co/F7QjOoavKO
Happy to present first European comparison of cilta-cel vs ide-cel for #myeloma #ASH24:
-Cilta-cel with better ORR, CR, PFS
-Similar NRM
-Peak CAR-T expansion day 14 for cilta-cel vs day 7 for ide-cel
👉associated with response and with ICANS for cilta-cel
@ash-hematology.bsky.social
Honored to be featured on the @ash-hematology.bsky.social ASH News Daily #ASH24 follow list! I'll be posting on both my Twitter (https://buff.ly/3Zy7BLc) and BS (https://buff.ly/3B9SpKU), so please do follow! https://buff.ly/49iWb1d
cc @rahulbanerjeemd.bsky.social @shematologist.bsky.social @nicogagelmann.bsky.social
